Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nomacopan - Akari Therapeutics

Drug Profile

Nomacopan - Akari Therapeutics

Alternative Names: Coversin; EV 576; PAS-coversin; rEV 576; rVA576

Latest Information Update: 21 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Evolutec
  • Developer Akari Therapeutics; Evolutec
  • Class Anti-inflammatories; Antiasthmatics; Antirheumatics; Eye disorder therapies; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathy; Guillain-Barre syndrome; Bullous pemphigoid
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Phase II Bullous pemphigoid; Thrombotic microangiopathy
  • Phase I/II Keratoconjunctivitis
  • Preclinical Rheumatoid arthritis; Uveitis
  • No development reported Guillain-Barre syndrome; Myasthenia gravis; Sjogren's syndrome
  • Discontinued Asthma; Autoimmune disorders; Inflammation

Most Recent Events

  • 10 Jan 2020 AKARI Therapeutics temporarily suspends the phase III CAPSTONE trial for Paroxysmal nocturnal hemoglobinuria in Kazakhstan; Lithuania and Sri Lanka (NCT03588026)
  • 10 Jan 2020 Interim efficacy and adverse events data from the phase III CAPSTONE trial for Paroxysmal nocturnal haemoglobinuria released by Akari Therapeutics
  • 10 Jan 2020 Updated efficacy results from the phase II COBALT trial for Paroxysmal nocturnal haemoglobinuria released by Akari Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top